Akèy › Maladi poumon › Arizona
Etid klinik pou Maladi poumon nan Arizona
9 etid pou Maladi poumon ap chèche patisipan nan sit nan Arizona.
Vil nan Arizona
Tèks ofisyèl etid la (Anglè)
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- Research Site, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT05624450Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Palo Verde Hematology Oncology, Glendale
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06765109American Lung Association (ALA) Lung Health Cohort
- University of Arizona-Tuscon, Tucson
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 25 a 35 · Tout sèks · Mizajou Sep 23, 2026 · NCT04543461A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
- Chandler Clinical Trials, Chandler
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Sep 22, 2026 · NCT06977581A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Banner MD Anderson Cancer Center, Gilbert
- Banner University Medical Center Phoenix, Phoenix
- The University of Arizona Cancer Center - North Campus, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06119581Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
- University of Arizona- Tuscon, Tucson
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07059091A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 102, Phoenix
- GC2501 Study Site 107, Scottsdale
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Aug 11, 2026 · NCT07555483Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- Banner Health MD Anderson, Gilbert
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Jun 26, 2026 · NCT04614103Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
- HonorHealth Research Institute, Scottsdale
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Nov 12, 2025 · NCT05975983Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.